The Social Chain AG

  • WKN: A1YC99
  • ISIN: DE000A1YC996
  • Land: Deutschland

Nachricht vom 11.11.2021 | 14:32

The Social Chain AG: BaFin approves securities prospectus for admission of shares for trading in the regulated market of the stock exchange in Frankfurt am Main

The Social Chain AG / Key word(s): IPO/Regulatory Approval
The Social Chain AG: BaFin approves securities prospectus for admission of shares for trading in the regulated market of the stock exchange in Frankfurt am Main

11-Nov-2021 / 14:32 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of an insider information pursuant to Article 17 of Regulation (EU) No 596/2014

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, "UNITED STATES") OR TO ANY U.S. PERSON (AS DEFINED BELOW), CANADA, AUSTRALIA OR JAPAN OR ANY OTHER COUNTRY IN WHICH SUCH PUBLICATION MAY BE UNLAWFUL OR IN WHICH THE OFFERING OF SECURITIES IS SUBJECT TO REGULATORY RESTRICTIONS. THERE ARE OTHER RESTRICTIONS. PLEASE SEE THE IMPORTANT NOTE AT THE END OF THIS PUBLICATION.

The Social Chain AG: BaFin approves securities prospectus for admission of shares for trading in the regulated market of the stock exchange in Frankfurt am Main

Berlin, 11 November 2021 - The Bundesanstalt für Finanzdienstleistungsaufsicht ("BaFin") today approved the securities prospectus of The Social Chain AG (WKN: A1YC99, ISIN: DE000A1YC996, Ticker: PU11) ("TSC") for the purpose of admission of all issued shares of TSC including all shares which so far were traded in the open market of the stock exchange in Düsseldorf, to the regulated market of the stock exchange in Frankfurt am Main, with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations (Prime Standard).

Furthermore, the securities prospectus addresses the admission of 2,855,000 new shares, which shall be issued to the shareholders of the DS Holding GmbH by way of a capital increase in kind in return for a transfer of a part of the shares in the DS Holding GmbH.

TSC expects notice of approval by the Frankfurt Stock Exchange during the course of today.

Begin of trading of the shares of TSC (first trading day) in the Prime Standard of the Frankfurt stock exchange is expected tomorrow, 12 November 2021.

www.socialchain.com

Contact:
Jana Walker I Investor Relations
Gormannstr. 22
10119 Berlin
+49 30 208 48 40 10
ir@socialchain.com


Important note

This announcement constitutes neither an offer nor a solicitation to purchase or subscribe for securities of the Company.

This announcement is not intended for distribution, directly or indirectly, in or into the United States or within the United States and may not be distributed to U.S. persons (as such term is defined in Regulation S under the Securities Act) or publications with a general circulation in the United States. This announcement does not constitute or form part of any offer to sell or the solicitation of an offer to purchase or subscribe for any securities in the United States. The securities are not and will not be registered under the Securities Act and may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration under the Securities Act. The Company does not intend to conduct a public offering of securities in the United States.

The securities referred to in this announcement will not be offered or sold in Canada, Australia or Japan, or to or for the account of persons resident in Canada, Australia or Japan. No action has been taken to offer, acquire or distribute the securities in any jurisdiction where this is not permitted.

This release contains statements relating to the future. These statements are based on current views, expectations and assumptions of the Company's management and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied. Actual results, results or events could differ materially from those described herein due to factors affecting the Company, including, but not limited to, changes in the general economic environment or competitive situation, capital market risks, foreign exchange rate fluctuations and competition from other companies, and changes in foreign or domestic laws or regulations, including, but not limited to, the tax environment. The Company assumes no obligation to update any statements relating to the future.




Contact:
Jana Walker | Investor Relations
ir@socialchain.com

11-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021